Home ➤ Life Science ➤ Diagnostics ➤ Europe Breast and Prostate Cancer Diagnostics Market
Europe Breast and Prostate Cancer Diagnostics Market
Published date: Nov 2025 • Formats:
Request Sample Schedule a Call

Europe Breast and Prostate Cancer Diagnostics Market By Test (Liquid Biopsy, Tumor Biomarkers Tests, In Situ Hybridization, Immunohistochemistry, Imaging, and Biopsy), By Application (Breast Cancer and Prostate Cancer), By End-user (Cancer Research Institutes, Independent Diagnostic Laboratories, Hospital Associated Labs, Diagnostic Imaging Centers, and Others), Region and Companies – Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2025-2034

  • Published date: Nov 2025
  • Report ID: 165889
  • Number of Pages: 398
  • Format:
  • keyboard_arrow_up
    • 1. Executive Summary
      • 1.1. Definition
      • 1.2. Market Snapshot
      • 1.3. Market Overview
      • 1.4. Segment Overview
      • 1.5. Regional Overview
      • 1.6. Competitive Landscape
      • 1.7. Taxonomy
      • 1.8. Industry Voices
    • 2. Market Overview
      • 2.1. Market Insights and Industry Overview
      • 2.2. Market Dynamics
        • 2.2.1. Drivers
        • 2.2.2. Restraints
        • 2.2.3. Opportunities
        • 2.2.4. Key Europe Breast and Prostate Cancer Diagnostics Market Trends
      • 2.3. Technology Landscape
      • 2.4. Regulatory Framework
      • 2.5. Sustainability and ESG (Environmental, Social, Governance)
      • 2.6. Opportunity Map Analysis
      • 2.7. Opportunity Orbits
      • 2.8. PESTLE Analysis
      • 2.9. PORTER’S Five Force Analysis
      • 2.10. Drivers & Restraints Impact Analysis
      • 2.11. Value Chain Analysis
        • 2.11.1. List of Raw Materials Suppliers
        • 2.11.2. List of Europe Breast and Prostate Cancer Diagnostics Manufacturers
        • 2.11.3. List of Dealer/Distributors
      • 2.12. Regional Market Share and BPS Analysis
      • 2.13. Impact of Macro-economic Factors/Geopolitical Factors
    • 3. Europe Breast and Prostate Cancer Diagnostics Market Analysis and Forecast, By Segment, 2020-2034
      • 3.1. Key Findings
      • 3.2. Europe Breast and Prostate Cancer Diagnostics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Test, 2020-2034
      • 3.3. Europe Breast and Prostate Cancer Diagnostics Market Attractiveness Analysis, By Test
        • 3.3.1. Liquid biopsy
          • 3.3.1.1. Insights
          • 3.3.1.2. Key Takeaways
        • 3.3.2. Tumor biomarkers tests
          • 3.3.2.1. Insights
          • 3.3.2.2. Key Takeaways
        • 3.3.3. In situ hybridization
          • 3.3.3.1. Insights
          • 3.3.3.2. Key Takeaways
        • 3.3.4. Immunohistochemistry
          • 3.3.4.1. Insights
          • 3.3.4.2. Key Takeaways
        • 3.3.5. Imaging
          • 3.3.5.1. Insights
          • 3.3.5.2. Key Takeaways
        • 3.3.6. Biopsy
          • 3.3.6.1. Insights
          • 3.3.6.2. Key Takeaways
      • 3.4. Europe Breast and Prostate Cancer Diagnostics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Application, 2020-2034
      • 3.5. Europe Breast and Prostate Cancer Diagnostics Market Attractiveness Analysis, By Application
        • 3.5.1. Breast cancer
          • 3.5.1.1. Insights
          • 3.5.1.2. Key Takeaways
        • 3.5.2. Prostate cancer
          • 3.5.2.1. Insights
          • 3.5.2.2. Key Takeaways
      • 3.6. Europe Breast and Prostate Cancer Diagnostics Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By End-user, 2020-2034
      • 3.7. Europe Breast and Prostate Cancer Diagnostics Market Attractiveness Analysis, By End-user
        • 3.7.1. Cancer research institutes
          • 3.7.1.1. Insights
          • 3.7.1.2. Key Takeaways
        • 3.7.2. Independent diagnostic laboratories
          • 3.7.2.1. Insights
          • 3.7.2.2. Key Takeaways
        • 3.7.3. Hospital associated labs
          • 3.7.3.1. Insights
          • 3.7.3.2. Key Takeaways
        • 3.7.4. Diagnostic imaging centers
          • 3.7.4.1. Insights
          • 3.7.4.2. Key Takeaways
        • 3.7.5. Others
          • 3.7.5.1. Insights
          • 3.7.5.2. Key Takeaways
    • 4. Competitive Landscape & Company Profiles
      • 4.1. Market Competition Scenario Analysis, By Company
        • 4.1.1. Key Takeaways
      • 4.2. Overview of Major Market Players
      • 4.3. Competitor Landscape
      • 4.4. Strategic Mapping
      • 4.5. Company Life Cycle Analysis
      • 4.6. Company Market Share Analysis
      • 4.7. Company Profiles
        • 4.7.1. Siemens Healthcare GmbH
          • 4.7.1.1. Company Details
          • 4.7.1.2. Business Overview
          • 4.7.1.3. Product Portfolio
          • 4.7.1.4. Financial Insights
          • 4.7.1.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 4.7.1.6. SWOT Analysis
          • 4.7.1.7. Geographic Footprint
        • 4.7.2. QIAGEN N.V.
          • 4.7.2.1. Company Details
          • 4.7.2.2. Business Overview
          • 4.7.2.3. Product Portfolio
          • 4.7.2.4. Financial Insights
          • 4.7.2.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 4.7.2.6. SWOT Analysis
          • 4.7.2.7. Geographic Footprint
        • 4.7.3. Koninklijke Philips N.V.
          • 4.7.3.1. Company Details
          • 4.7.3.2. Business Overview
          • 4.7.3.3. Product Portfolio
          • 4.7.3.4. Financial Insights
          • 4.7.3.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 4.7.3.6. SWOT Analysis
          • 4.7.3.7. Geographic Footprint
        • 4.7.4. General Electric (GE HealthCare)
          • 4.7.4.1. Company Details
          • 4.7.4.2. Business Overview
          • 4.7.4.3. Product Portfolio
          • 4.7.4.4. Financial Insights
          • 4.7.4.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 4.7.4.6. SWOT Analysis
          • 4.7.4.7. Geographic Footprint
        • 4.7.5. F.Hoffmann-La Roche Ltd.
          • 4.7.5.1. Company Details
          • 4.7.5.2. Business Overview
          • 4.7.5.3. Product Portfolio
          • 4.7.5.4. Financial Insights
          • 4.7.5.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 4.7.5.6. SWOT Analysis
          • 4.7.5.7. Geographic Footprint
        • 4.7.6. Danaher (Cepheid)
          • 4.7.6.1. Company Details
          • 4.7.6.2. Business Overview
          • 4.7.6.3. Product Portfolio
          • 4.7.6.4. Financial Insights
          • 4.7.6.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 4.7.6.6. SWOT Analysis
          • 4.7.6.7. Geographic Footprint
        • 4.7.7. Cook Group Inc.
          • 4.7.7.1. Company Details
          • 4.7.7.2. Business Overview
          • 4.7.7.3. Product Portfolio
          • 4.7.7.4. Financial Insights
          • 4.7.7.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 4.7.7.6. SWOT Analysis
          • 4.7.7.7. Geographic Footprint
        • 4.7.8. Bio Rad Laboratories Inc.
          • 4.7.8.1. Company Details
          • 4.7.8.2. Business Overview
          • 4.7.8.3. Product Portfolio
          • 4.7.8.4. Financial Insights
          • 4.7.8.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 4.7.8.6. SWOT Analysis
          • 4.7.8.7. Geographic Footprint
        • 4.7.9. Becton, Dickinson and Company
          • 4.7.9.1. Company Details
          • 4.7.9.2. Business Overview
          • 4.7.9.3. Product Portfolio
          • 4.7.9.4. Financial Insights
          • 4.7.9.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 4.7.9.6. SWOT Analysis
          • 4.7.9.7. Geographic Footprint
        • 4.7.10. Agilent Technologies, Inc.
          • 4.7.10.1. Company Details
          • 4.7.10.2. Business Overview
          • 4.7.10.3. Product Portfolio
          • 4.7.10.4. Financial Insights
          • 4.7.10.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 4.7.10.6. SWOT Analysis
          • 4.7.10.7. Geographic Footprint
    • 5. Methodology and Data Source
      • 5.1. Methodology/Research Approach
      • 5.2. Market Size Estimation
      • 5.3. Market Breakdown and Data Triangulation
      • 5.4. Data Source
      • 5.5. Secondary Sources
      • 5.6. Primary Sources
      • 5.7. Appendix
      • 5.8. Disclaimer
    • List of Tables
      • Table 1. Europe Breast and Prostate Cancer Diagnostics Market Value (US$ Mn), By Test, 2020-2034
      • Table 2. Europe Breast and Prostate Cancer Diagnostics Market Value (US$ Mn), By Application, 2020-2034
      • Table 3. Europe Breast and Prostate Cancer Diagnostics Market Value (US$ Mn), By End-user, 2020-2034
    • List of Figures
      • Figure 1. Europe Breast and Prostate Cancer Diagnostics Market Snapshot: Market Value (US$ Mn), 2020-2034
      • Figure 2. Opportunity Map
      • Figure 3. Opportunity Orbit
      • Figure 4. Regional Market Share and BPS Analysis in Europe Breast and Prostate Cancer Diagnostics Market
      • Figure 5. Europe Breast and Prostate Cancer Diagnostics Market Analysis, By Test, 2020, 2024 and 2034
      • Figure 6. Europe Breast and Prostate Cancer Diagnostics Market Attractiveness Analysis, By Test
      • Figure 7. Europe Breast and Prostate Cancer Diagnostics Market Analysis, By Application, 2020, 2024 and 2034
      • Figure 8. Europe Breast and Prostate Cancer Diagnostics Market Attractiveness Analysis, By Application
      • Figure 9. Europe Breast and Prostate Cancer Diagnostics Market Analysis, By End-user, 2020, 2024 and 2034
      • Figure 10. Europe Breast and Prostate Cancer Diagnostics Market Attractiveness Analysis, By End-user
    • Siemens Healthcare GmbH
    • QIAGEN N.V.
    • Koninklijke Philips N.V
    • General Electric (GE HealthCare)
    • Hoffmann-La Roche Ltd.
    • Danaher (Cepheid)
    • Cook Group Inc.
    • Bio Rad Laboratories Inc.
    • Becton, Dickinson and Company
    • Agilent Technologies, Inc.

Related Reports

Our Clients

  • Our Clients
Europe Breast and Prostate Cancer Diagnostics Market
  • 165889
  • Nov 2025
    • ★★★★★
      ★★★★★
    • (142)
add_shopping_cart Buy Now
Trusted by more than 17382 organizations globally
  • Client Logo
  • Client Logo
  • Client Logo
✖
Request a Sample Report
We'll get back to you as quickly as possible

Find Help
Legal
Explore
Secured Payment Options
Secured Payment Options